- |||||||||| blonanserin / Generic mfg.
Journal: Preparation and release pattern study of long-term controlled release Blonanserin microspheres. (Pubmed Central) - Sep 29, 2024 When the ratio of 15?kDa and 75?kDa was 1:9 (F3), the Bn-MS had a low burst release rate, moderate release rate, no release hysteresis period, a long release period of up to 35?days, and a stable release pattern close to the zero level. The results of the release mechanism study indicated that the hybrid PLGA improved the release behavior of the microspheres by adjusting the dissolution degradation rate of Bn-MS, which in turn affected the release mechanism of the microspheres.
- |||||||||| Lonasen tape (blonanserin transdermal patch) / Nitto Denko, Sumitomo Pharma
Review, Journal, Metastases: Novel therapies for nausea and vomiting in advanced illness and supportive cancer care. (Pubmed Central) - Jun 10, 2024 Isopropyl alcohol aromatherapy has been successfully used in the emergency department for nausea and vomiting with an onset to benefit more rapidly than standard antiemetics. Isopropyl alcohol prep pads can be used for home-going antiemetic therapy and as a bridge to treating acute nausea until standard antiemetics take effect.
- |||||||||| blonanserin / Generic mfg.
Journal: Reduced sociability in a prenatal immune activation model: Modulation by a chronic blonanserin treatment through the amygdala-hippocampal axis. (Pubmed Central) - Jun 28, 2023 Low dose of blonanserin and haloperidol altered GABA and glutamate-related mRNA levels, the E/I ratio, and Bdnf long 3'UTR mRNA levels in the ventral hippocampus and amygdala, but did not attenuate behavioral impairments. These results strongly implicate changes in PV expression, PV(+) GABAergic interneuron density, and Bdnf long 3'UTR expression levels, particularly in the dorsal hippocampus, in the pathophysiology and treatment responses of MIA-induced schizophrenia and highlight the therapeutic potential of blonanserin for developmental stress-related schizophrenia.
- |||||||||| blonanserin / Generic mfg.
Behavioural and molecular effects of the antipsychotic drug blonanserin in the chronic mild stress model (Poster area [IN-PERSON]) - Oct 13, 2022 - Abstract #ECNP2022ECNP_541; These competing parameters need careful consideration in designing optimal super-SNEDDS for pre-clinical and clinical application. Our data provide new insights into the therapeutic properties and potential use of blonanserin and provide further support for the role of oxidative stress in mediating the link between chronic stress exposure and the etiology of psychiatric disorders.
- |||||||||| blonanserin / Generic mfg.
Journal: The type rather than the daily dose or number of antipsychotics affects the incidence of hyperglycemic progression. (Pubmed Central) - Feb 25, 2022 Furthermore, changes in HbA1c levels 6 mo after the initiation of zotepine treatment were significantly higher than those following blonanserin and haloperidol treatments...Our study indicated that the type of antipsychotic had a greater affect on the incidence of hyperglycemic progression than the daily dose of antipsychotics or their number. Among these, zotepine was most likely to increase the incidence of hyperglycemic progression, suggesting the need for caution when these antipsychotics are prescribed.
- |||||||||| Rexulti (brexpiprazole) / Lundbeck, Otsuka
Preclinical, Journal: Inhibitory Effects of Antipsychotics on the Contractile Response to Acetylcholine in Rat Urinary Bladder Smooth Muscles. (Pubmed Central) - Dec 16, 2021 The remaining nine antipsychotics (pipamperone (a butyrophenone), sulpiride, sultopride, tiapride, nemonapride (benzamides), risperidone, paliperidone (SDAs), aripiprazole, and brexpiprazole (dopamine partial agonists)) did not inhibit ACh-induced contractions at concentrations up to 10 M. These findings suggest that chlorpromazine, levomepromazine, zotepine, olanzapine, quetiapine, and clozapine should be avoided by elderly people with urinary disorders.
- |||||||||| blonanserin / Generic mfg.
Journal: Behavioral and molecular effects of the antipsychotic drug blonanserin in the chronic mild stress model. (Pubmed Central) - Nov 21, 2021 Our results demonstrated that the antipsychotic treatment normalizes the CMS-induced emotionality deficits, an effect that may be due to its ability in modulating, within the prefrontal cortex, redox mechanisms, a molecular dysfunction associated with several psychiatric disorders. These evidences provide new insights in the therapeutic properties and potential use of blonanserin as well as in its mechanisms of action and provide further support for the role of oxidative stress in the pathophysiology of psychiatric disorders.
- |||||||||| risperidone / Generic mfg., blonanserin / Generic mfg.
Clinical, P3 data, Retrospective data, Journal: Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8-week, multicenter, double-blind, randomized controlled study. (Pubmed Central) - May 29, 2021 Blonanserin exerted the similar efficacy to risperidone in both positive and negative symptoms in schizophrenia with a lower risk of prolactin increase, weight gain, and orthostatic hypotension compared with risperidone. Blonanserin will serve as a favorable treatment option for schizophrenia in daily clinical practice.
- |||||||||| blonanserin / Generic mfg.
Journal: Refractory dry eye disease associated with Meige's syndrome induced by long-term use of an atypical antipsychotic. (Pubmed Central) - May 15, 2021 Our study confirmed that blonanserin occupied both D and D receptors in patients with schizophrenia. In patients with refractory dry eye disease, especially those with involuntary movements of the eyelids with oromandibular dystonia, it is important to ask about their psychotropic medications and to consider the possibility of drug-induced Meige's syndrome and discontinuation of medications, if possible.
- |||||||||| Journal: Transdermal Delivery of Antipsychotics: Rationale and Current Status. (Pubmed Central) - Sep 23, 2020
Despite the current availability of a large number of antipsychotics, only a few of these drugs (e.g. aripiprazole, asenapine, blonanserin, chlorpromazine, haloperidol, olanzapine, prochlorperazine, quetiapine, and risperidone) have been developed as transdermal delivery systems...However, few clinical trials on transdermal delivery of antipsychotic drugs are available and only delivery systems containing asenapine and blonanserin have shown interesting clinical results in terms of pharmacokinetic data, efficacy, and tolerability. Recently, the transdermal patch formulation of blonanserin was approved in Japan for the treatment of schizophrenia.
|